Apr 30,2024

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Caris Life Sciences and COTA, Inc. have announced a collaboration to expand their multi-modal data offerings for biopharmaceutical drug development and patient care in oncology. By combining Caris' extensive genomic, transcriptomic, proteomic, and imaging data with COTA's curated clinical data, the collaboration aims to provide a comprehensive real-world data solution to drive next-generation therapeutic development and advance patient care in cancer treatment. Caris' molecular-rich database, along with COTA's clinical data from over two million cancer patients across various care settings, will offer valuable insights for optimizing cancer treatments and improving patient outcomes.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 29,2024 TOP STORY

Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients

Huma Therapeutics together with Merck KGaA, Darmstadt, Germany, announced the launch of their bladder cancer treatment companion app in the United Kingdom. The UK launch marks a significant milestone in the partnership between Huma and Merck KGaA, Darmstadt, Germany, announced in November 2023. Additional markets are planned for launch in the coming year, and may support delivery of care for a range of cancers. The companion app is designed to support patients and caregivers in navigating the complexities of bladder cancer treatment by providing a reliable source of information and support throughout the treatment journey. UK-based patient organisations and specialist cancer care centres were involved in and piloting the bladder cancer treatment journey app in advance of the launch.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 26,2024

NOVEL STUDY TO ASSESS WAVE HEALTH FOR STEM CELL TRANSPLANT PATIENTS DELIVERS PROMISING RESULTS AND VALUABLE REAL-WORLD DATA

Interim findings from a study by Treatment Technologies & Insights (TTI) and Wilmot Cancer Institute reveal promising results for Wave Health's mobile app. The study is designed to assess the feasibility and usability of a customized version of the Wave Health mobile app for self-monitoring and symptom reporting by adult recipients of Allogeneic Stem Cell Transplantation (SCT) at risk for Chronic Graft-versus-host Disease (cGVHD). Participants engage with the app over a four-week period, tracking daily activities, mood, and symptoms, and completing weekly symptom reviews. 88% of participants used the app weekly, indicating feasibility, while 89% found it easy to use, highlighting its potential to enhance cGVHD symptom monitoring in stem cell transplant recipients.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 25,2024

Hoag Health System Selects PathAI and the AISight Image Management System to Support the Transition To Digital and AI-enabled Pathology

PathAI announced that Hoag Health System, the leading health system in the southern California region, will adopt the AISight Image Management System (IMS) as their primary platform, powering their transition to digital pathology. The transition from analog, glass-slide-based pathology to digital pathology continues to accelerate across anatomic pathology, globally. AISight serves as a central hub for case management, image management, and best-in-class artificial intelligence tools from PathAI and third-party partners, to enable a broad spectrum of histopathology use cases. Importantly, PathAI will collaborate with Hoag and their laboratory information system (LIS) provider to build a bi-directional integration between AISight and their Epic Beaker LIS instance to ensure a fully integrated pathologist experience.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Apr 22,2024

Elekta and GE HealthCare’s MIM Software enter significant collaboration to deliver leading cancer treatment planning solutions

Elekta and MIM Software Inc., a leading provider of medical imaging management and artificial intelligence solutions, recently acquired by GE HealthCare, announce their collaboration to combine best-of-breed solutions for advanced treatment planning in the delivery of radiation therapy. The collaboration is expected to spur innovation within treatment planning and utilize Elekta’s and MIM Software’s respective strengths in regional markets to make solutions available globally. "... This is a natural expansion of Elekta ONE, combining the best dose planning capabilities with MIM's proven track record of physician preferred tools. Clinically, it means delivering on improved automation and adaptive therapy planning, as well as greater speed and accuracy..." said Maurits Wolleswinkel, Elekta’s President Linac and Software Solutions.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 19,2024

Experimental AI predicts whether cancer drugs will work

Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer treatment, bringing the concept of personalised therapy a step closer to reality. Their AI platform, called PERCEPTION, focuses on the transcriptome – a collection of all the mRNAs expressed in a cell – and was trained on publicly available data taken from large-scale studies that screened drugs against cancer cell lines. Current approaches to matching patients to drugs rely on bulk sequencing of tumour DNA and RNA, which takes an average of all the cells in a tumour sample, according to the NCI. However, tumours can have many different cell types, and researchers believe these subpopulations may respond differently to specific drugs. That could explain why some patients do not respond to certain drugs or develop resistance to them.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 17,2024 TOP STORY

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

COTA, a leader in real-world data (RWD) and analytics for oncology, has announced a strategic collaboration with Sanofi aimed at accelerating oncology trials, particularly for multiple myeloma, using RWD and artificial intelligence (AI). The collaboration with Sanofi will focus on addressing key questions relevant to multiple myeloma, aiming to deepen understanding of the disease's treatment landscape. The project's potential outcomes could influence future clinical study designs and inform the interpretation of ongoing and future trial results within the current standard of care for multiple myeloma patients.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 10,2024

NCCN and Flatiron Health Announce Collaboration to Improve Cancer Care Quality with Real-World Data

Flatiron Health has renewed its collaboration with the National Comprehensive Cancer Network (NCCN). Originating in 2014, the partnership established a cloud-based repository of NCCN Member Institution data, known as the NCCN Quality & Outcomes Database. Crystal S. Denlinger, MD, CEO of NCCN, emphasizes the commitment to providing high-quality cancer care worldwide through leveraging data. The renewal aims to further research with real-world data, enhance cancer care quality, and support quality improvement initiatives at participating NCCN Member Institutions. Neal Meropol, MD, VP of Research Oncology at Flatiron Health, highlights the collaboration's role in improving care standards and addressing evidence gaps in cancer treatment.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 11,2024 TOP STORY

Bayer, Google partner on AI for time-pressed radiologists

Bayer has partnered with Google Cloud to enhance its artificial intelligence-powered platform for radiologists, aiming to streamline diagnosis processes and utilize medical imaging data for research and development. The platform, developed over the past few years, assists radiologists in reviewing various scan images and prioritizing patient treatments. The first version of the platform will launch later this year for testing in the US and Europe.

COLLABORATION PARTNERSHIP

#r&d

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Apr 01,2024

Flatiron Health and Smirta Innovations Announce Partnership to Enable OncoSmart® for OncoEMR® Customers

 

Flatiron Health and Smirta have announced a partnership to integrate Smirta's OncoSmart scheduling tool into Flatiron's OncoEMR electronic medical record system used by oncology practices. This collaboration aims to optimize scheduling in oncology practices, reducing burnout, improving operational efficiency, and enhancing the scheduling experience for providers and patients. As claimed in the press release, practices using Smirta's scheduling tools have seen significant reductions in extended clinic hours and increased capacity. The partnership aims to support oncologists and healthcare providers in delivering better patient care by simplifying workflows and maximizing resource utilization.

COLLABORATION PARTNERSHIP

#product & service

#platform

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY